Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of Oncology(2021)10.1016/j.annonc.2021.02.006Source: DataRank Database

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types is a research paper published in Annals of Oncology (2021). On theSindex it has a DataRank of 10.8. It has been cited 1,072 times, with 200 citing works in its 1-hop citation network.

N/A

10.8DataRank · unranked

Scored on demand from live citation data

Open Access1,072 citations · 200 citing works in its network

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 70.40)OA: hybridTopics (32)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 10%Citation Network 90%

Base Score Contribution

1.0

From this paper's citation signal

Citation Network Contribution

9.8

From 200 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 200 citers.

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
Clinical Cancer Research2021585 citations17 referencesContributes 0.375
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
Journal for ImmunoTherapy of Cancer202166 citations17 referencesContributes 0.247
The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival
Nature Communications2021199 citations23 referencesContributes 0.230
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy
JAMA Network Open2023124 citations22 referencesContributes 0.219
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
JAMA Oncology2022389 citations28 referencesContributes 0.213

Authors (16)

P.G. Pilié,N.U. Rashid,Leonie Voorwerk ORCID,Maarten Slagter ORCID,Marleen Kok ORCID

Live enrichment

PubMed:33736924 PMC:PMC8053682 OpenAlex:https://openalex.org/W3136653115

NCI NIH HHS

Grant: R01 CA218287

NCI NIH HHS

Grant: K99 CA240689

National Cancer Institute

Prostate Cancer Foundation

Susan G Komen for the Cure

Cancer Prevention and Research Institute of Texas

Kidney Cancer Association

FWCI

70.40

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttp://www.annalsofoncology.org/article/S092375342100123X/pdf

publisherhttp://www.annalsofoncology.org/article/S092375342100123X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S092375342100123X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S092375342100123X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.annonc.2021.02.006

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesFerroptosis and cancer prognosisBiomarkers, TumorHumansImmune Checkpoint InhibitorsMaleMutationNeoplasmsTreatment Outcome

MeSH Terms

Immune Checkpoint InhibitorsHumansMaleMutationNeoplasmsBiomarkers, TumorTreatment Outcome

Keywords

MedicineBlockadeImmune checkpointCancerMutationImmune systemOncologyInternal medicineImmunologyGeneticsGeneReceptorBiomarkerImmune Checkpoint BlockadeTumor Mutation Burden

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Construction of a single nucleotide variant score-related gene-based prognostic model in hepatocellular carcinoma: analysis of multi-independent databases and validation in vitro

10.6084/m9.figshare.17047310.v1figshare

Additional file 1 of Construction of a single nucleotide variant score-related gene-based prognostic model in hepatocellular carcinoma: analysis of multi-independent databases and validation in vitro

10.6084/m9.figshare.17047310figshare

Additional file 1 of Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

10.6084/m9.figshare.19603483.v1figshare

Additional file 1 of Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

10.6084/m9.figshare.19603483figshare

Additional file 1 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024713.v1figshare

Additional file 1 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024713figshare

Additional file 3 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024722.v1figshare

Additional file 3 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024722figshare

Additional file 4 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024725.v1figshare

Additional file 4 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024725figshare

Additional file 5 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024728.v1figshare

Additional file 5 of Potential prognosis index for m6A-related mRNA in cholangiocarcinoma

10.6084/m9.figshare.20024728figshare

Additional file 1 of Bias and inconsistency in the estimation of tumour mutation burden

10.6084/m9.figshare.20423962.v1figshare

Additional file 1 of Bias and inconsistency in the estimation of tumour mutation burden

10.6084/m9.figshare.20423962figshare

Additional file 1 of Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

10.6084/m9.figshare.20501909.v1figshare

Additional file 1 of Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

10.6084/m9.figshare.20501909figshare

Additional file 2 of Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

10.6084/m9.figshare.20501912.v1figshare

Additional file 2 of Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

10.6084/m9.figshare.20501912figshare

Additional file 3 of Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

10.6084/m9.figshare.20501915.v1figshare

Additional file 3 of Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

10.6084/m9.figshare.20501915figshare